Climb Bio (CLYM) Net Cash Flow (2020 - 2026)
Climb Bio's (CLYM) quarterly Net Cash Flow came in at -$27.3 million in Q1 2026, up 53.03% YoY from -$17.9 million in Q1 2025, and down 376.55% on a QoQ basis from $9.9 million in Q4 2025.
Climb Bio (CLYM) Net Cash Flow (2020 - 2026) Analysis & Trends
Climb Bio (CLYM) has 7 years of Net Cash Flow data on file, last reported at -$27.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 53.03% year-over-year to -$27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$20.7 million (up 72.8% YoY) and the FY2025 annual result came in at -$51.5 million, down 769.94% from the prior year.
- Net Cash Flow declined to -$27.3 million in Q1 2026, from $9.9 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $118.1 million in Q2 2024 to a low of -$77.1 million in Q3 2024.
- A 5-year average of -$2.3 million and a median of $1.7 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2023 — Net Cash Flow sank 654.12% — and 2024, when it soared 1337.58%.
- Tracing CLYM's Net Cash Flow over 5 years: stood at $5.8 million in 2022, then surged by 519.13% to $36.1 million in 2023, then tumbled by 263.18% to -$58.9 million in 2024, then soared by 116.78% to $9.9 million in 2025, then sank by 376.55% to -$27.3 million in 2026.
- The last three Net Cash Flow figures came in at -$27.3 million (Q1 2026), $9.9 million (Q4 2025), and $3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Climb Bio | 1.24 Bn | 1.24 Bn | - | 35.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.89 Mn |
| Jun 30, 2026 | 35.89 Mn |
| Mar 31, 2026 | -27.33 Mn |
| Mar 31, 2026 | -27.33 Mn |
| Dec 31, 2025 | 9.88 Mn |
| Dec 31, 2025 | 9.88 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Sep 30, 2025 | 3.12 Mn |
| Jun 30, 2025 | -6.36 Mn |
| Jun 30, 2025 | -6.36 Mn |
| Mar 31, 2025 | -58.19 Mn |
| Mar 31, 2025 | -58.19 Mn |
| Dec 31, 2024 | -58.89 Mn |
| Dec 31, 2024 | -58.89 Mn |
| Sep 30, 2024 | -77.07 Mn |
| Sep 30, 2024 | -77.07 Mn |
| Jun 30, 2024 | 118.09 Mn |
| Jun 30, 2024 | 118.09 Mn |
| Mar 31, 2024 | 11.95 Mn |
| Mar 31, 2024 | 11.95 Mn |